IMMUNOME INC (IMNM) Stock News

Immunome to Present at Upcoming March Conferences

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Analyst Expectations For Immunome's Future

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Mentions: IVA TRIB OPT NAOV ...

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Immunome Announces Proposed Public Offering of Common Stock

Immunome Stock Sees RS Rating Jump To 91

Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.

Mentions: ADMA SIGA CPRX

IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immunome (NASDAQ:IMNM) just reported results for the second quarter of 2024.Imm...

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 Small-Cap Stocks With Big Growth Potential

Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space.

Mentions: HNRG NVDA AENT

Nectin Therapeutics Licenses Novel Antibodies to Immunome

/PRNewswire/ -- Nectin Therapeutics, Ltd., a biotechnology company developing novel immunotherapies and antibody drug conjugates (ADC) to address tumor...

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024

IMNM stock results show that Immunome missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Immunome Appoints Phil Tsai as Chief Technical Officer